EAM
KURA icon

Eventide Asset Management’s Kura Oncology KURA Stock Holding History

Eventide Asset Management’s Portfolio KURA Stock Details KURA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-1,790,144
Closed -$32.8M – 145
2022
Q2 		$32.8M Sell
1,790,144
-270,900
-13% -$3.9M 0.7% 50
2022
Q1 		$33.1M Buy
2,061,044
+700,000
+51% +$10.1M 0.52% 62
2021
Q4 		$19.1M Hold
1,361,044
– – 0.24% 99
2021
Q3 		$25.5M Buy
1,361,044
+657,044
+93% +$12.4M 0.34% 81
2021
Q2 		$14.7M Sell
704,000
-913,573
-56% -$22.7M 0.2% 106
2021
Q1 		$45.7M Buy
1,617,573
+557,573
+53% +$17.6M 0.68% 55
2020
Q4 		$34.6M Buy
1,060,000
+660,000
+165% +$23.2M 0.53% 60
2020
Q3 		$12.3M Buy
+400,000
New +$8.83M 0.24% 97

Other funds holding KURA

EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Holocene Advisors
Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Eventide Asset Management's KURA Position: Q3 2022 in Review

Eventide Asset Management sold out of Kura Oncology (KURA) in Q3 2022, closing a stake of 1,790,144 shares — an estimated $32.8M sold.

Eventide Asset Management first reported a position in KURA in Q3 2020 and held it in 8 quarters. The position peaked at $45.7M in Q1 2021. 148 funds tracked by Wall St. Rank hold KURA as of Q3 2022.

  • Eventide Asset Management reported no remaining Kura Oncology position as of Q3 2022 after selling out during the quarter.
  • Eventide Asset Management sold 1,790,144 Kura Oncology shares in Q3 2022, an estimated $32.8M.
  • Eventide Asset Management first reported a position in Kura Oncology in Q3 2020 and held it in 8 quarters.
  • Eventide Asset Management's Kura Oncology position peaked at $45.7M in Q1 2021.
  • 148 funds tracked by Wall St. Rank held Kura Oncology as of Q3 2022.

Based on Eventide Asset Management's 13F filing for Q3 2022, filed 14 Nov 2022.